• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SanBio touts 1-year data on stem cell transplant for stroke

November 4, 2016 By Sarah Faulkner

SanBio touts 1-year data on stem cell transplant for strokeSanBio Inc. (TYO:4592) released 1-year interim data from the phase 1/2a, open-label, single-arm dose escalation study of its intracerebral stem cell implant designed for stroke patients.

The Mountain View, Calif.-based company touted the results, which indicated that itsSB623 stem cell treatment was generally safe, well-tolerated and associated with improved motor functions in patients  suffering with chronic impairment following an ischemic stroke.

SanBio presented interim results from the study at the American Congress of Rehabilitation Medicine Conference last week, and claims that the study is the 1st of its kind in the U.S.

“When SB623 cells were administered in patients who had previously suffered a stroke, we saw statistically significant improvement compared to baseline in motor function, and this improvement appears to be sustainable,” SanBio’s head of clinical development Dr. Jerry Liu said in prepared remarks. “We are encouraged by this data. And hope to provide an effective treatment for the millions of people living with impairments following a stroke.”

The trial enrolled 18 patients with chronic motor deficits 6 months to 5 years following an ischemic stroke. Researchers gave patients injections of the genetically modified allogeneic mesenchymal stem cells, which were derived from the bone marrow of healthy adult donors.

The company reported 6 serious adverse events, such as subdural hematoma, seizure and pneumonia, but said that they were not likely related to the stem cell treatment.

“The data suggest that patients were able to tolerate SB623 cells at 12 months following procedure, and further demonstrates the potential for SB623 cells as a possible treatment option for patients with chronic impairments following a stroke,” Dr. Lawrence Wechsler from the University of Pittsburgh Medical Center explained.

Filed Under: Clinical Trials, Featured, Neurological, Research & Development, Stem Cells Tagged With: SanBio Inc

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS